GVR Report cover Animal Biotechnology Market Size, Share & Trends Report

Animal Biotechnology Market Size, Share & Trends Analysis Report By Product Type (Diagnostics Tests, Vaccines, Drugs), By Application, By Animal Type, By End-use, By Region, And Segment Forecasts, 2022 - 2030

  • Report ID: GVR-4-68039-958-0
  • Number of Report Pages: 150
  • Format: PDF, Horizon Databook
  • Historical Range: 2017 - 2020
  • Forecast Period: 2022 - 2030 
  • Industry: Healthcare

Report Overview

The global animal biotechnology market size was valued at USD 22.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 9.2% from 2022 to 2030. Key growth drivers include the rising need to develop genetically modified therapeutic proteins providing better resistance to diseases, application in cancer treatment, and heightened preventive care for pets. Other aspects contributing to the industry growth comprise improved demand for the usage of animals in agriculture, meat, and animal-based products, growing awareness regarding animal health and welfare, expanding role of animals in the development of pharmaceuticals for humans, and growing animal adoption.

U.S. animal biotechnology market size, by product type, 2020 - 2030 (USD Billion)

Rising cancer incidence in dogs is further fueling industry growth. As per the National Cancer Institute, nearly 6 million new cancer diagnoses are made in dogs every year. Moreover, the Veterinary Cancer Society projected that 1 in 4 dogs will develop cancer at some point, and almost 50% of dogs over age 10 will develop cancer. The obesity prevalence amongst the pet population is increasing all over the world. Owing to the fact that excess fat and body weight enhances the load on joints, overweightness is directly linked with osteoarthritis in dogs, which results in difficulty in movement. As per Petpedia. co, 30% of all dogs in the U.S. are obese. Therefore, these trends combined with the other factors are anticipated to positively drive the market.

The COVID-19 pandemic crisis has overburdened public health systems in many nations and emphasized the strong requirement for sustainable investment in health systems. The COVID-19 pandemic forced nearly everyone to work remotely. Medium- and small-sized businesses faced difficulties as there are restrictions on vet clinic visits due to the pandemic. Besides, in a globalized world that depends on supply chain logistics, the COVID-19 pandemic and the measures undertaken to curb its spread created bottlenecks. For instance, nations such as Romania have banned the export to Non-European Union nations, thus creating severe demand-supply problems in the animal feed sector. Moreover, the consumption of fish and meat has declined drastically throughout the globe, which, in turn, declined the demand for feed additives, thus impacting the market growth.

An increasing number of initiatives and campaigns are implemented by the government to promote animal health, which may increase the demand for animal health biotechnology in the coming years. For example, in January 2021, the governments of Canada and Ontario are providing up to $4 million through the Canadian Agricultural Partnership to offer farmers improved access to veterinary services when and where they require it. Likewise, TRPVB is a partnership initiative between the Department of Biotechnology, India, and TANUVAS-Chennai to enable a collaborative and coordinated approach to the transformation of technologies in the field of veterinary vaccines, biologicals, and diagnostics.

Innovations and recent advances in immunology, molecular biology, and genetic engineering have expanded the scope of animal health biotechnology. Breakthroughs in molecular marker technology advancements, farm animal genome sequencing, and other biotechnology applications will offer new possibilities for research to enhance and modernize the animal health industry. In December 2021, The Asian Development Bank has signed a contract to take a stake in Zenex Animal Health India Private Limited with an investment of up to $10 million, to expand Zenex’s manufacturing and distribution of quality animal health products. Asian Development Bank will assist Zenex’s investments in maintenance expenditure, working capital, and research and development of new products.

The growing initiative to educate on animal genetic testing is further anticipated to drive the market. For example, the Veterinary Genetics Laboratory at the UC Davis School of Veterinary Medicine has released an updated and improved website along with numerous new tests for the veterinary community. Furthermore, the growing incidence of zoonotic diseases is increasing the demand for advanced diagnosis. Brazil had the second-largest cattle inventory in the world in 2021. In recent months, Zoonoses have dominated the headlines. After the occurrence of a highly contagious and virulent strain of avian flu in Asia and the bovine spongiform encephalopathy (BSE) discovery in the western U.S., tens of millions of birds have been killed and hundreds of cattle slaughtered.

Product Type Insights

The vaccines segment held the largest revenue share of over 25.0% in 2021. The growth of the vaccine segment is primarily attributed to the increasing burden of animal infections. These infections are naturally transmitted from animals to humans owing to contaminated food and water consumption or direct communication with infected humans or animals. Vaccination is an effective way to lower the disease burden in animals, and it plays an important role in preventive healthcare and disease control. Additionally, the increase in vaccine introductions for animals by the key market players is projected to drive the segment. In December 2021, Indian Immunologicals Ltd. introduced Goat Pox Vaccine (Raksha Goat Pox). Likewise, in May 2021, Boehringer Ingelheim India released its poultry vaccine VAXXITEK HVT+IBD. Such launches will lead to the increased adoption of vaccines, fueling segment growth.

The diagnostics tests segment is anticipated to witness exponential growth throughout the forecast period. The growth in this segment is attributed to factors, such as growing animal health expenditure, rising incidence of zoonotic diseases, increase in the number of veterinary practitioners, and increasing disposable income levels in developing territories. Besides, the overall market is determined by deeply understanding the demand for these products from veterinary hospitals, clinics, labs, etc., and increasing R&D investments from industry players. In August 2021, INDICAL BIOSCIENCE GmbH acquired the Check-Points, Dutch R&D-focused corporation. INDICAL is a global leader in the advancement of complete solutions for molecular and immunological veterinary testing.

Application Insights

The preventive care of animals segment held the largest revenue share of over 25.0% in 2021 due to the growing adoption of companion animals. The advent of pet parents as part of the pet humanization trend is a key revenue-generating trend in the market. Besides, an international survey by HABRI and Zoetis indicates a direct relationship between the human-animal bond and consistent veterinary care. The study including participants from the U.S., France, the U.K., Spain, Germany, Japan, Brazil, and China showed a clear global phenomenon of the improved bond between humans and pets, with 95% of respondents stating that they consider their pets to be a part of the family. Thus, such a human-animal bond advances better preventive care.

The drug development application is anticipated to witness exponential growth throughout the forecast period. Leveraging the monoclonal antibodies in animal health generated great potential to address unmet needs. For instance, in September 2021, Boehringer Ingelheim and Invetx announced that they have entered a collaboration agreement to develop innovative, species-specific monoclonal antibody biotherapeutics targeting a broad range of infections in the veterinary species, primarily focused on dogs and cats. This partnership will address Boehringer Ingelheim’s commitment to delivering unmet needs in the rapidly growing animal health biotechnology market.

Animal Type Insights

The livestock segment held the largest share of over 60.0% in 2021. Livestock is becoming increasingly vital in the growth of agriculture in developing nations. The contributions made by livestock to both agriculture and gross domestic product have risen in various nations. The demand for livestock products is a function of income in different parts of the world. The growing urban population and changes in diet and lifestyle are promoting growth in livestock production, thus contributing to the segment growth. Furthermore, government initiatives undertaken for livestock vaccinations promote market growth.

For instance, in June 2022, Indonesia launched a countrywide livestock vaccination program as the number of cattle affected with foot and mouth disease surged to more than 151,000. In the livestock segment, cattle held the largest revenue share in 2021. The U.S. is home to about 93.8 million cattle and calves as of 2020. The companion animal type segment is likely to grow lucratively during the forecast period owing to an increase in the demand for efficient animal care and the pet-human bond owing to the associated health benefits. Banfield Pet Hospital, in January 2021, confirmed a huge boom in U.S. pet ownership, thus supporting the segment growth.

End-use Insights

The veterinary hospitals and clinics segment held the largest revenue share of over 70.0% in 2021 and is anticipated to continue leading the market over the forecast period. The availability of a wide range of treatment and diagnostic options in veterinary hospitals and clinics is a high-impact rendering growth driver for this segment. An increase in the incidence of zoonotic diseases caused by globalization and climate changes is expected to drive the demand for diagnostic procedures, which is expected to drive the point-of-care testing/in-house testing segment in the coming years.

Global animal biotechnology market share, by end-use, 2021 (%)

The others segment is expected to witness the fastest growth over the forecast period. Veterinary research institutes and universities are expected to grow at a lucrative rate over the forecast period. This can be attributed to the growing R&D funding to develop advanced diagnostic tools and therapeutically advanced vaccines and medicines. Research institutes are primarily responsible for the development of these diagnostics.

Regional Insights

North America accounted for the largest revenue share of over 30.0% in 2021 owing to the high animal awareness levels and improved healthcare infrastructure. The presence of healthcare programs and a rise in the number of initiatives to promote animal health are factors anticipated to increase the growth potential in this region. Moreover, high R&D spending in the region is anticipated to boost market growth in North America. In October 2021, Zoetis Inc. expanded its manufacturing and development facility in Tullamore, Ireland, which substantially expanded its capacity for producing veterinary monoclonal antibodies.

Animal Biotechnology Market Trends by Region

The Asia Pacific market is expected to witness the fastest growth over the forecast period. The rise in middle-class households, increased disposable income, acceptance of pet animals, new product launches, and high demand for animal proteins are some of the key factors expected to boost the growth of the market in the region. In June 2022, India's first COVID-19 vaccine Anocovax for animals unveiled. Besides Anocovac, the Agriculture Minister of India launched the 'CAN-CoV-2 ELISA kit' -- specific nucleocapsid protein-based indirect ELISA kit -- for antibody detection against SARS-CoV-2 in canines.

Key Companies & Market Share Insights

Major players observed growth during the pandemic despite the restriction and supply chain disruption. Consolidated revenues of Neogen Corporation were USD 418.2 million in fiscal 2020, an upsurge of 1.0% compared to 2019. Multinational companies are investing in increased production capacity, expanding sites in Asia and China; and building more partnerships. Small-to-medium size corporations view emerging nations with growing economies as high-potential markets.

The key players are involved in various strategies such as new product type developments, distribution agreements, and expansion strategies to improve their market penetration. For instance, in March 2022, Hester Biosciences Limited expanded into the Pet Care sector. Likewise, in August 2021, Elanco closed the acquisition of Kindred Biosciences. Additionally, in October 2021, Embark Veterinary, Inc., has released its DNA test for purebred dogs. The kit offers purebred owners exclusive, actionable health information to assist in pinpoint diagnostic, treatment plans, and monitoring that can easily be shared with a veterinarian. Some prominent players in the global animal biotechnology market include:

  • Zoetis

  • Boehringer Ingelheim International GmbH

  • Biogénesis Bagó

  • Merck & Co., Inc.

  • Virbac

  • Elanco

  • Idexx Laboratories

  • Heska Corporation

  • Indian Immunologicals Ltd.


  • Kareo, Inc.

  • NXGN Management, LLC

Animal Biotechnology Market Report Scope

Report Attribute


Market size value in 2022

USD 24.20 billion

Revenue forecast in 2030

USD 49.07 billion

Growth Rate

CAGR of 9.2% from 2022 to 2030

Base year for estimation


Historical data

2017 - 2020

Forecast period

2022 - 2030

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product type, application, animal type, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; the Middle East and Africa

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; Japan; India; China; Australia; Brazil; Mexico, Argentina; South Africa; Saudi Arabia

Key companies profiled

Zoetis; Boehringer Ingelheim International GmbH; Biogénesis Bagó; Merck & Co., Inc.; Virbac; Elanco; Idexx Laboratories; Heska Corporation; Indian Immunologicals Ltd.; HESTER BIOSCIENCES LIMITED

Customization scope

Free report customization (equivalent to up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail of customized purchase options to meet your exact research needs. Explore purchase options


Global Animal Biotechnology Market Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2017 to 2030. For this study, Grand View Research has segmented the global animal biotechnology market report based on product type, application, animal type, end-use, and region:

Global Animal Biotechnology Market Segmentation

  • Product Type Outlook (Revenue, USD Million, 2017 - 2030)

    • Diagnostics Tests

    • Vaccines

    • Drugs

    • Reproductive and Genetic

    • Feed Additives

  • Application Outlook (Revenue, USD Million, 2017 - 2030)

    • Diagnosis of Animal Diseases

    • Treatment of Animal Diseases

    • Preventive Care of Animals

    • Drug Development

    • Others

  • Animal Type Outlook (Revenue, USD Million, 2017 - 2030)

    • Companion

      • Dogs

      • Cats

      • Horses

      • Others

    • Livestock

      • Poultry

      • Swine

      • Cattle

      • Sheep & Goats

      • Fish

  • End-use Outlook (Revenue, USD Million, 2017 - 2030)

    • Laboratories

    • Point-of-Care Testing/In-house Testing

    • Veterinary Hospitals & Clinics

    • Others

  • Regional Outlook (Revenue, USD Million, 2017 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • U.K.

      • Germany

      • France

      • Italy

      • Spain

    • Asia Pacific

      • Japan

      • China

      • India

      • Australia

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa

      • South Africa

      • Saudi Arabia

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.